Journal article icon

Journal article

A comparison between 12 versus 20 weeks of trimethoprim-sulfamethoxazole as oral eradication treatment for melioidosis: an open-label, pragmatic, multicenter, non-inferiority, randomized controlled trial

Abstract:

Background Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand.

Methods For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 week...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/cid/ciaa1084

Authors


More by this author
Role:
Author
ORCID:
0000-0002-1075-4135
Expand authors...
More from this funder
Grant:
106698/Z/14/A milestone
More from this funder
Grant:
106698/B/14/Z milestone
More from this funder
Grant:
089275/F/09/Z milestone
More from this funder
Grant:
089275/H/09/Z Milestone Baht
Publisher:
Oxford University Press Publisher's website
Journal:
Clinical Infectious Diseases Journal website
Volume:
73
Issue:
11
Pages:
e3627–e3633
Publication date:
2020-07-29
Acceptance date:
2020-07-27
DOI:
EISSN:
1537-6591
ISSN:
1058-4838
Pmid:
32725199
Pubs id:
1124969
Local pid:
pubs:1124969
Language:
English
Keywords:
Format:
Print-Electronic

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP